Pfizer Inc

Pfizer Inc. is a global biopharmaceutical company engaged in the discovery, development, manufacture, marketing, sale, and distribution of biopharmaceutical products worldwide. The company operates primarily through its Global Biopharmaceuticals Business (Biopharma) segment and Pfizer CentreOne contract manufacturing division. Its commercial structure includes the Pfizer U.S. Commercial Division, the Pfizer International Commercial Division, and the Global Hospital and Biosimilars Division. Pfizer's portfolio spans primary care (including Eliquis for blood clots, the Prevnar pneumococcal vaccine family, Comirnaty COVID-19 vaccine, Paxlovid antiviral, and Abrysvo RSV vaccine), oncology (including Ibrance for breast cancer, Padcev for urothelial and bladder cancer, Xtandi for prostate cancer, Lorbrena for ALK+ lung cancer, and several other targeted therapies), and specialty care (including the Vyndaqel family for transthyretin amyloid cardiomyopathy, Xeljanz, and Cibinqo). The company also markets biosimilars and operates a contract manufacturing business. Pfizer has a robust late-stage pipeline including berobenatide, a potential first-in-class monthly GLP-1 receptor agonist for obesity, a 25-valent pneumococcal conjugate vaccine candidate, and sigvotatug vedotin in multiple oncology settings. Pfizer recently entered a strategic licensing and collaboration agreement with Innovent Biologics for 12 early-stage cancer medicines including antibody-drug conjugates and multi-specific antibodies. Updated Oct 8, 2026